Gregory Fulchiero
MOHS-Micrographic Surgery · Altoona, PANPI 1942414115
Payments from drug & device makers
Across 806 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$11K
- AbbVie$3K
- Johnson & Johnson$2K
- Amgen$861
- Sanofi$824
- E.r. Squibb & Sons, L.L.C.$805
- plus $6K from 31 others
What the payments were for
- Consulting fees$9,50040%
- Travel & lodging$7293%
- Food & beverage$13,06155%
- Education$4782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 37 | $10,838 |
| AbbVie | 193 | $2,516 |
| Johnson & Johnson | 77 | $1,787 |
| Amgen | 45 | $861 |
| Sanofi | 36 | $824 |
| E.r. Squibb & Sons, L.L.C. | 64 | $805 |
| Novartis | 32 | $608 |
| UCB, Inc. | 33 | $594 |
| Pfizer | 39 | $564 |
| Regeneron Healthcare Solutions, Inc. | 19 | $504 |
| LEO Pharma Inc. | 25 | $498 |
| Lilly USA, LLC | 32 | $483 |
| Dermavant Sciences, Inc. | 26 | $435 |
| Galderma Laboratories, L.p. | 33 | $395 |
| Incyte Corporation | 15 | $279 |
| Genentech USA, Inc. | 15 | $265 |
| Biofrontera Inc. | 13 | $237 |
| Arcutis Biotherapeutics, Inc. | 13 | $185 |
| Bristol Myers Squibb | 3 | $140 |
| Boehringer Ingelheim | 8 | $139 |
| Organon | 9 | $131 |
| Mayne Pharma Commercial LLC | 8 | $128 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $127 |
| Prugen, Inc. Pharmaceuticals | 4 | $67 |
| Acelrx Pharmaceuticals, Inc. | 3 | $48 |
| Dermira, Inc. | 2 | $46 |
| Organogenesis Inc. | 1 | $45 |
| Merz North America, Inc. | 2 | $42 |
| Verrica Pharmaceuticals Inc. | 2 | $35 |
| Misonix Inc | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Bioventus LLC | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| VYNE Pharmaceuticals Inc. | 1 | $14 |
| DUSA Pharmaceuticals, Inc. | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
| Kerecis Limited | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,769 in reported general payments places this provider in the 95th percentile of 48 mohs-micrographic surgery providers in Pennsylvania.
See all mohs-micrographic surgery providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 52 | $766,813 |
| ErivedgeVismodegib | 43 | $626,343 |
| OtezlaApremilast | 95 | $443,038 |
| Dupixent SyringeDupilumab | 72 | $296,204 |
| XolairOmalizumab | 51 | $137,194 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $129,916 |
| Dupixent PenDupilumab | 25 | $91,028 |
| RinvoqUpadacitinib | 11 | $69,302 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 30 | $20,713 |
| Fluocinonide | 242 | $15,607 |
| Clobetasol Propionate | 324 | $11,497 |
| Imiquimod | 296 | $10,430 |
| Triamcinolone Acetonide | 933 | $9,477 |
| Metronidazole | 180 | $8,305 |
| Ketoconazole | 264 | $6,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Erivedge | $265 | $626,34343 claims |
| AmgenOtezla | $861 | $443,03895 claims |
| AbbVieRinvoq | $2,516 | $69,30211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 mohs-micrographic surgery providers in Pennsylvania.
Other mohs-micrographic surgery in Altoona
- Jason SchoenfeldPhiladelphia$960K
- Cynthia BartusAllentown$10K
- Ernest BenedettoPhiladelphia$9K
- Carmen CampanelliYardley$8K
- Aradhna SaxenaFort Washington$8K
- Nicole VelezCranberry Township$6K
- Justin VujevichPittsburgh$6K
- Preetha AgarwalPittsburgh$6K
- Julian NgoCarlisle$5K
- Adam BlechmanYardley$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.